Form 8-K
8-K — AbbVie Inc.
Accession: 0001104659-26-091269
Filed: 2026-08-05
Period: 2026-08-04
CIK: 0001551152
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — tm2621452d4_8k.htm (Primary)
EX-1.1 — EXHIBIT 1.1 (tm2621452d4_ex1-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: tm2621452d4_8k.htm · Sequence: 1
false
0001551152
0001551152
2026-08-04
2026-08-04
0001551152
us-gaap:CommonStockMember
exch:XNYS
2026-08-04
2026-08-04
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2026-08-04
2026-08-04
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2026-08-04
2026-08-04
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2026-08-04
2026-08-04
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2026-08-04
2026-08-04
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2026-08-04
2026-08-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 4, 2026
ABBVIE
INC.
(Exact name of registrant as specified in its charter)
Delaware
001-35565
32-0375147
(State of Incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
1
North Waukegan Road
North
Chicago, Illinois 60064-6400
(Address of principal executive offices, including zip code)
(847) 932-7900
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, $0.01 Par Value
ABBV
New
York Stock Exchange
NYSE Texas
0.750%
Senior Notes due 2027
ABBV27
New
York Stock Exchange
2.125%
Senior Notes due 2028
ABBV28
New
York Stock Exchange
2.625%
Senior Notes due 2028
ABBV28B
New
York Stock Exchange
2.125%
Senior Notes due 2029
ABBV29
New
York Stock Exchange
1.250%
Senior Notes due 2031
ABBV31
New
York Stock Exchange
Item 8.01. Other Events.
On August 4, 2026,
AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the
“Underwriting Agreement”) with Morgan Stanley & Co. LLC, BofA
Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the
several underwriters named in Schedule II therein (collectively, the “Underwriters”),
pursuant to which AbbVie agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its senior
floating rate notes due 2028 (the “Floating Rate Notes”),
$1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “2028
Notes”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “2030
Notes”), $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031 (the “2031 Notes”),
$1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033 (the “2033
Notes”), $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036 (the “2036
Notes”), $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038 (the “2038
Notes”), $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 (the “2056
Notes”) and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066 (the “2066
Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2030 Notes, the 2031 Notes, the 2033 Notes, the
2036 Notes, the 2038 Notes and the 2056 Notes, the “Notes”).
The price to the public was
100% of the principal amount for the Floating Rate Notes, 99.970% of the principal amount for the 2028 Notes, 99.862% of
the principal amount for the 2030 Notes, 99.977% of the principal amount for the 2031 Notes, 99.889% of the principal amount
for the 2033 Notes, 99.832% of the principal amount for the 2036 Notes, 99.810% of the principal amount for the 2038 Notes,
99.441% of the principal amount for the 2056 Notes and 99.843% of the principal amount for the 2066 Notes.
The offering of each series
of Notes has been registered under the Securities Act of 1933, as amended (the “Act”), pursuant to AbbVie’s
registration statement on Form S-3ASR (File No. 333-284980) (the “Registration Statement”), dated as of February
14, 2025. The terms of the Notes are further described in AbbVie’s preliminary prospectus supplement dated August 4, 2026, as filed
with the Securities and Exchange Commission (the “SEC”) on August 4, 2026, and the final prospectus supplement, dated
August 4, 2026, to be filed with the SEC on or prior to August 6, 2026 (the “Prospectus Supplement”). The closing of
the sale of the Notes is expected to occur on August 18, 2026, subject to customary closing conditions.
The net proceeds from the
sale of the Notes, after deducting the underwriting discounts and estimated offering expenses, are expected to be approximately $9.93 billion.
AbbVie intends to use these net proceeds (i) to fund a portion of its cash payment obligations in connection with its acquisition
of Apogee Therapeutics, Inc. (“Apogee”) and to pay fees, expenses and other amounts in connection therewith and (ii)
for other general corporate purposes, which may include the repayment or repurchase of outstanding debt. The net proceeds from the issuance
of the Notes will reduce commitments under AbbVie’s $10.0 billion 364-Day delayed draw term loan facility entered into in connection
with the acquisition of Apogee.
The Underwriting Agreement
includes customary representations, warranties and covenants by AbbVie. It also provides for customary indemnification by each of AbbVie
and the respective Underwriters against certain liabilities arising out of or in connection with the sale of the Notes and for customary
contribution provisions in respect of those liabilities.
As more fully described under
the caption “Underwriting—Other Relationships” in the Prospectus Supplement, some of the underwriters in respect
of the Underwriting Agreement and/or their affiliates have in the past performed, and may in the future from time to time perform, investment
banking, financial advisory, lending and/or commercial banking services, or other services, for AbbVie and its subsidiaries, for which
they have received, and may in the future receive, customary compensation and expense reimbursement.
Please refer to the Prospectus
Supplement for additional information regarding the offering of the Notes and the terms and conditions of the Notes. The foregoing summary
of the Notes does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement,
which is attached as Exhibit 1.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are
provided as part of this Form 8-K:
1.1
Underwriting Agreement, dated August 4, 2026, by and among AbbVie Inc., Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC (acting for themselves and as representatives of the several underwriters named therein).
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward Looking Statements
Some statements in this Current Report on Form
8-K and the documents incorporated by reference into this Current Report on Form 8-K are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). The words “believe,” “expect,”
“anticipate,” “project” and similar expressions and uses of future or conditional verbs generally identify “forward
looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements
are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied
in the forward-looking statements. Where, in any forward looking statement, an expectation or belief as to future results or events is
expressed or implied, such expectation or belief is based on the current plans and expectations of AbbVie management, and expressed in
good faith, and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved
or accomplished. Factors that could cause actual results or events to differ materially from those anticipated include, but are not limited
to, the matters described under Item 1A, “Risk Factors,” and Item 7, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2025,
which has been filed with the SEC. AbbVie notes these factors for investors as permitted by the PSLRA. AbbVie does not undertake, and
specifically declines, any obligation to update the forward-looking statements included in this Current Report on Form 8-K to reflect
events or circumstances after the date hereof, unless AbbVie is required by applicable securities law to do so.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBVIE INC.
Date: August 5, 2026
By:
/s/ Scott
T. Reents
Scott T. Reents
Executive Vice President, Chief Financial Officer
EX-1.1 — EXHIBIT 1.1
EX-1.1
Filename: tm2621452d4_ex1-1.htm · Sequence: 2
Exhibit 1.1
ABBVIE INC.
$500,000,000 Senior Floating Rate Notes due 2028
$1,000,000,000 4.500% Senior Notes due 2028
$1,250,000,000 4.650% Senior Notes due 2030
$1,500,000,000 4.875% Senior Notes due 2031
$1,250,000,000 5.050% Senior Notes due 2033
$1,500,000,000 5.300% Senior Notes due 2036
$1,000,000,000 5.450% Senior Notes due 2038
$1,500,000,000 6.000% Senior Notes due 2056
$500,000,000 6.100% Senior Notes due 2066
UNDERWRITING AGREEMENT
August 4, 2026
Morgan Stanley & Co. LLC
1585 Broadway
New York, New York 10036
BofA Securities, Inc.
One Bryant Park
New York, New York 10036
J.P. Morgan Securities LLC
270 Park Avenue
New York, New York 10017
SG Americas Securities, LLC
245 Park Avenue
New York, New York 10167
As representatives of the several Underwriters
named in Schedule II hereto
Ladies and Gentlemen:
AbbVie Inc., a Delaware corporation
(the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P.
Morgan Securities LLC and SG Americas Securities, LLC (together, the “Representatives”) and the other several underwriters
named in Schedule II hereto (together with the Representatives, the “Underwriters”) pursuant to this Underwriting
Agreement (this “Agreement”) the principal amount of its debt securities identified in Schedule I hereto (the
“Securities”), to be issued pursuant to the indenture dated as of November 8, 2012 (the “Base Indenture”)
between the Company and U.S. Bank Trust Company, National Association (successor to U.S. Bank National Association), as Trustee (the “Trustee”),
as supplemented by Supplemental Indenture No. 13, to be dated as of August 18, 2026, between the Company and the Trustee (the
“Supplemental Indenture”, and the Base Indenture as supplemented by the Supplemental Indenture, the “Indenture”).
The Company has filed with
the Securities and Exchange Commission (the “Commission”) a registration statement, including a prospectus, (the file
number of which is set forth in Schedule I hereto) on Form S-3, relating to securities (the “Shelf Securities”),
including the Securities, to be issued from time to time by the Company. The registration statement as amended to the date of this Agreement,
including the information (if any) deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430A
or Rule 430B under the Securities Act of 1933, as amended (the “Securities Act”), including all exhibits thereto
(but excluding Form T-1), is hereinafter referred to as the “Registration Statement,” and the related prospectus
covering the Shelf Securities dated February 14, 2025 is hereinafter referred to as the “Basic Prospectus.” The
Basic Prospectus, as supplemented by the prospectus supplement specifically relating to the Securities in the form first used to confirm
sales of the Securities (or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant
to Rule 173 under the Securities Act) is hereinafter referred to as the “Prospectus,” and the term “preliminary
prospectus” means any preliminary form of the Prospectus. For purposes of this Agreement, “free writing prospectus”
has the meaning set forth in Rule 405 under the Securities Act and relating to the offering of the Securities, “Time of
Sale Prospectus” means the documents and pricing information set forth opposite the caption “Time of Sale Prospectus”
in Schedule I hereto, and “broadly available road show” means a “bona fide electronic road show”
as defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used
herein, the terms “Registration Statement,” “Basic Prospectus,” “preliminary prospectus,”
“Time of Sale Prospectus” and “Prospectus” shall include the documents, if any, incorporated by
reference therein as of the date hereof. The terms “supplement,” “amendment,” and “amend”
as used herein with respect to the Registration Statement, the Basic Prospectus, the Time of Sale Prospectus, any preliminary prospectus
or the Prospectus shall include all documents subsequently filed by the Company with the Commission pursuant to the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), that are deemed to be incorporated by reference therein.
The Company understands that
the Underwriters propose, subject to the provisions hereof and the selling restrictions disclosed in the Prospectus, to make a public
offering of the Securities as soon as the Representatives deem advisable after this Agreement has been executed and delivered.
1. Representations
and Warranties of the Company. The Company represents and warrants to, and agrees with, each of the Representatives that:
(a) No
Stop Order; Status as a Well-Known Seasoned Issuer. The Registration Statement has become effective; no stop order suspending the
effectiveness of the Registration Statement is in effect, and no proceedings for such purpose or pursuant to Section 8A under the
Securities Act are pending before or, to the knowledge of the Company, threatened by the Commission. If the Registration Statement is
an automatic shelf registration statement as defined in Rule 405 under the Securities Act, the Company is a well-known seasoned issuer
(as defined in Rule 405 under the Securities Act) eligible to use the Registration Statement as an automatic shelf registration statement
and the Company has not received notice that the Commission objects to the use of the Registration Statement as an automatic shelf registration
statement;
2
(b) Registration
Statement, Prospectus and Disclosure at Time of Sale. (i) Each document, if any, filed or to be filed pursuant to the Exchange
Act and incorporated by reference in the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in all material
respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii) each part of the
Registration Statement, when such part became effective, did not contain, and each such part, as amended or supplemented, if applicable,
will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein not misleading, (iii) the Registration Statement as of the date hereof does not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein not misleading, (iv) the Registration Statement and the Prospectus comply, and as amended or supplemented, if applicable,
will comply in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder,
(v) each broadly available road show, if any, when considered together with the Time of Sale Prospectus, does not contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (vi) the Time of Sale Prospectus does not, and at the time of each sale of the Securities
in connection with the offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined
in Section 4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading, and (vii) the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to (A) statements or omissions in the Registration Statement, the Time of Sale
Prospectus or the Prospectus based upon the Underwriters’ Information (as defined in Section 8(b) below) relating
to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein or (B) that
part of the Registration Statement that constitutes the Statement of Eligibility (Form T-1) under the Trust Indenture Act of 1939,
as amended (the “Trust Indenture Act”), of the Trustee;
(c) Ineligible
Issuer. The Company is not an “ineligible issuer” in connection with the offering pursuant to Rules 164, 405 and
433 under the Securities Act. Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under
the Securities Act in connection with the offering of the Securities has been, or will be, filed with the Commission in accordance with
the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus
that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by
or on behalf of or used or referred to by the Company as of its date and at all times through the completion of the offering of the Securities
complies or will comply in all material respects with the requirements of the Securities Act and the applicable rules and regulations
of the Commission thereunder; Except for the free writing prospectuses, if any, identified in Schedule I hereto, forming part of
the Time of Sale Prospectus, and electronic road shows, if any, each furnished to you before first use, the Company has not prepared,
used or referred to, and will not, without your prior consent, prepare, use or refer to, any free writing prospectus in connection with
the offering of the Securities;
3
(d) Incorporated
Documents. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus,
at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements
of the Securities Act and the Exchange Act and the rules and regulations of the Commission thereunder, as applicable, and, when read
together with the other information in the Prospectus, (a) at the time the Registration Statement became effective, (b) at the
Applicable Time and (c) at the Closing Date (as defined below) did not contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. As used in this Agreement, “Applicable Time” means 7:45 P.M. (New
York City time) on August 4, 2026;
(e) No
Material Adverse Change in Company Business. Neither the Company nor any of its subsidiaries has sustained since the date of the latest
audited financial statements included or incorporated by reference in the Registration Statement, Time of Sale Prospectus and the Prospectus
any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from
any labor dispute or court or governmental action, order or decree, in each case which is material to the Company and its subsidiaries
taken as a whole, otherwise than as set forth or contemplated in the Registration Statement, the Time of Sale Prospectus or the Prospectus;
and, since the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
there has not been any material change in the consolidated capital stock or any material increase in the consolidated long-term debt of
the Company and its subsidiaries, taken as a whole, or any material adverse change, or any development involving a prospective material
adverse change, in or affecting the business, financial position, shareholders’ equity or results of operations of the Company and
its subsidiaries, taken as a whole, otherwise than as set forth or contemplated in the Time of Sale Prospectus;
(f) Good
Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the
laws of the State of Delaware, has the corporate power and authority to own or lease its properties and conduct its business as described
in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus, and is duly qualified to transact business and
is in good standing in each jurisdiction in which the conduct of its business or the ownership or leasing of its property requires such
qualification, except where failure to be so qualified or in good standing would not, in the aggregate, have a material adverse effect
upon the Company and its subsidiaries, taken as a whole;
(g) Good
Standing of Subsidiaries. Each of the “significant subsidiaries” of the Company (as such term is defined in Rule 1-02(w) of
Regulation S-X promulgated under the Securities Act) has been duly incorporated, organized or formed, is validly existing as a corporation
or business entity in good standing under the laws of the jurisdiction of its incorporation, organization or formation, is duly qualified
to transact business and is in good standing in each jurisdiction in which the conduct of its business or the ownership or leasing of
its property requires such qualification, except where failure to be so qualified or in good standing would not, in the aggregate, have
a material adverse effect upon the Company and its subsidiaries, taken as a whole;
(h) Authorization
of this Agreement. This Agreement has been duly authorized, executed and delivered by the Company;
4
(i) Authorization
of the Securities. The Securities have been duly authorized and, when executed and authenticated and registered in the name of the
holders thereof in the register of holders maintained for such purposes, in each case, in accordance with the provisions of the Indenture,
and delivered to and paid for by the Underwriters, in accordance with the terms of this Agreement, will be valid and binding obligations
of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws relating to or affecting creditors’ rights generally and general principles of equity (collectively,
the “Enforceability Exceptions”), and will be entitled to the benefits of the Indenture, subject to the Enforceability
Exceptions and except as rights to indemnification and contribution may be limited under applicable law;
(j) Authorization
of the Indenture. The Indenture has been duly authorized and, assuming due execution and delivery by the Trustee, when executed and
delivered by the Company, will be a valid and binding agreement of the Company, enforceable in accordance with its terms, subject to the
Enforceability Exceptions. The Indenture and the Securities will conform to the descriptions thereof contained in the Time of Sale Prospectus
as amended or supplemented with respect to such Securities;
(k) Absence
of Defaults and Conflicts. The issue and sale of the Securities and the compliance by the Company with all of the provisions of the
Securities, the Indenture and this Agreement, and the consummation of the transactions herein and therein contemplated, will not (i) conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation
or imposition of any lien, charge or encumbrance upon any of the property or assets of the Company or any of its subsidiaries pursuant
to the terms of, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of
its subsidiaries is a party, or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of
the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the articles of incorporation
or by-laws, each as amended, of the Company or (iii) result in a violation of any applicable law, statute or any order, rule or
regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries, or any of their
respective properties, in any such case described in the preceding clause (i) or clause (iii) the effects of which
would, individually or in the aggregate, be materially adverse to the Company and its subsidiaries, taken as a whole;
(l) Absence
of Further Requirements. No consent, approval, authorization, order, registration or qualification of or with any such court or governmental
agency or body is required for the issue and sale of the Securities or the consummation by the Company of the transactions contemplated
by this Agreement, the Securities or the Indenture except such as have already been obtained or may be required by the securities or Blue
Sky laws of the various states in connection with the offer and sale of the Securities and except as would not, individually or in the
aggregate, be materially adverse to the Company’s ability to consummate the transactions contemplated by this Agreement, the Securities
or the Indenture or perform its obligations thereunder, as applicable;
5
(m) Absence
of Proceedings. Other than as set forth in the Time of Sale Prospectus, there are no legal or governmental proceedings pending to
which the Company or any of its subsidiaries is a party or of which any property of the Company or any of its subsidiaries is the subject
(including, without limitation, any proceedings before the United States Food and Drug Administration or comparable Federal, state, local
or foreign governmental bodies) that, individually or in the aggregate, would reasonably be expected to have a material adverse effect
on the business, financial position, shareholders’ equity or results of operations of the Company and its subsidiaries, taken as
a whole; and, to the Company’s knowledge, no such proceedings are threatened or contemplated by governmental authorities or threatened
by others;
(n) eXtensible
Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance
with the Commission’s rules and guidelines applicable thereto;
(o) Company
Financial Statements. Except as noted therein, (i) the consolidated financial statements of the Company, and the related notes
thereto, contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects
the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their
operations and changes in their combined cash flows for the periods specified; (ii) such financial statements have been prepared
in conformity with accounting principles generally accepted in the United States applied on a consistent basis; and (iii) the selected
financial data of the Company and its subsidiaries contained in the Time of Sale Prospectus present fairly the information shown therein
and have been compiled on a basis consistent with that of the financial statements of the Company contained in the Time of Sale Prospectus.
The statistical, industry-related and market-related data included in each of the Registration Statement, the Time of Sale Prospectus
and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate
and such data is consistent with the sources from which they are derived, in each case in all material respects;
(p) Compliance
with the Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the
rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402
related to loans and Sections 302 and 906 related to certifications;
(q) Accounting
Controls. The Company and its subsidiaries (i) make and keep accurate books and records in all material respects and (ii) maintain
internal accounting controls which provide reasonable assurance that (A) transactions are executed in accordance with management’s
authorization, (B) transactions are recorded as necessary to permit preparation of their financial statements and to maintain accountability
for their assets, (C) access to their assets is permitted only in accordance with management’s authorization and (D) the
reported accountability for their assets is compared with existing assets at reasonable intervals and appropriate action is taken with
respect to any difference;
(r) Disclosure
Controls. The Company has established, maintains and will maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of
the Exchange Act) which are designed to ensure that information required to be disclosed by the Company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported in accordance with the Exchange Act and the rules and
regulations thereunder. The Company has carried out evaluations, and the Company will carry out evaluations, under the supervision and
with the participation of the Company’s management, of the effectiveness of the design and operation of the Company’s disclosure
controls and procedures in accordance with Rule 13a-15 of the Exchange Act;
6
(s) Independent
Registered Public Accounting Firm. Ernst & Young LLP, which has audited and reported on certain financial statements of the
Company and its subsidiaries included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the
Prospectus and have audited the Company's internal control over financial reporting and management's assessment thereof, is an independent
registered public accounting firm with respect to the Company and its subsidiaries as required by the Securities Act and the Exchange
Act and the rules and regulations of the Commission and the PCAOB;
(t) Filing
of Prospectus. Each preliminary prospectus filed as part of the Registration Statement as originally filed or as part of any amendment
thereto, or filed pursuant to Rule 424 under the Securities Act, complied when so filed in all material respects with the Securities
Act and the applicable rules and regulations of the Commission thereunder;
(u) Pending
Proceedings and Examinations. The Registration Statement is not the subject of a pending proceeding or examination under Section 8(d) or
8(e) of the Securities Act, and the Company is not the subject of a pending proceeding under Section 8A of the Securities Act
in connection with the offering of the Securities;
(v) Anti-Corruption.
None of the Company, its subsidiaries, affiliates, directors or officers has taken any action in furtherance of an offer, payment, promise
to pay, or authorization or approval of the payment or giving or receipt of money, property, gifts or anything else of value, directly
or indirectly, to any “government official” (including any officer or employee of a government or government-owned or controlled
entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing,
or any political party or party official or candidate for political office) to improperly influence official action or secure an improper
advantage or to any person in violation of any applicable anti-corruption laws; the Company and its subsidiaries and affiliates have conducted
their businesses in compliance with applicable anti-corruption laws and have instituted and maintained policies and procedures designed
to promote and achieve compliance with such laws and with the representations and warranties contained in this paragraph, and neither
the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment,
promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable
anti-corruption laws;
(w) Investment
Company. The Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds
thereof as described in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus will not be, required to register
as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended;
(x) Anti-Money
Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with all
applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the
Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (“USA
PATRIOT Act”), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct
business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened, except for any such action, suit
or proceeding, individually or in the aggregate, as would not have a material adverse effect on the Company and its subsidiaries, taken
as a whole;
7
(y) OFAC.
(i) None
of the Company, its subsidiaries or, to the Company’s knowledge, any of their respective officers or directors is an individual
or entity (“Person”) that is an Embargoed Person; provided that if any subsidiary of the Company becomes an
Embargoed Person pursuant to clause (B)(3) of the definition thereof as a result of a country or territory becoming subject
to any applicable Sanctions program after the Closing Date, such Person shall not be an Embargoed Person so long as the Company is taking
reasonable steps to either obtain an appropriate license for transacting business in such country or territory or to cause such Person
to no longer reside, be organized or chartered or have a place of business in such country or territory and such Person’s residing,
being organized or chartered or having a place of business in such country or territory would not be reasonably expected to have a material
adverse effect on the Company and its subsidiaries, taken as a whole;
(ii) “Embargoed
Person” means (A) any country or territory that is the target of a sanctions program administered by U.S. Department of
Treasury’s Office of Foreign Assets Control (“OFAC”) or (B) any Person that (1) is or is owned or controlled
by one or more Persons publicly identified on the most current list of “Specially Designated Nationals and Blocked Persons”
published by OFAC, (2) is the target of a sanctions program or sanctions list administered by OFAC, the State Department of the United
States, the European Union or His Majesty’s Treasury (collectively, “Sanctions”) or (3) resides, is organized
or chartered, or has a place of business in a country or territory that is the subject of a Sanctions program administered by OFAC that
prohibits dealing with the government of such country or territory (unless such Person has an appropriate license to transact business
in such country or territory or otherwise is permitted to reside, be organized or chartered or maintain a place of business in such country
or territory without violating any Sanctions); and
(iii) Except
as permitted by Sanctions, the Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other Person:
8
(A) to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions; or
(B) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor or otherwise); and
(z) Cybersecurity;
Data Protection. Except as otherwise disclosed in the Time of Sale Prospectus and the Prospectus, (i) the Company has not been
notified of, and has no knowledge of any security breach or other compromise of or relating to any of the Company’s information
technology and computer systems, networks, hardware, software, data (including the data of its customers, employees, suppliers, vendors
and any third party data maintained by or on behalf of the Company), equipment or technology (collectively, “IT Systems and Data”),
except in the case of this clause (i) as would not, individually or in the aggregate, result in a material adverse effect
on the current or future consolidated financial position, stockholders’ equity or results of operations of the Company; (ii) the
Company is presently in compliance with applicable laws or statutes relating to the privacy and security of IT Systems and Data and to
the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually
or in the aggregate, result in a material adverse effect on the current or future consolidated financial position, stockholders’
equity or results of operations of the Company; and (iii) the Company has implemented backup and disaster recovery technology consistent
with industry standards and practices.
(aa) Taxes.
Except as would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a
whole, each of the Company and its subsidiaries has (i) filed all tax returns that are required to be filed by it or has requested
extensions thereof and (ii) paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it,
except for any such tax, assessment, fine or penalty that is currently being contested in good faith.
2. Agreements
to Sell and Purchase. The Company hereby agrees to sell to the several Underwriters, and each Underwriter, upon the basis of the representations
and warranties herein contained, but subject to the terms and conditions hereinafter stated, agrees, severally and not jointly, to purchase
from the Company, at purchase prices as set forth on Schedule I, in the respective principal amounts of Securities as set forth
opposite its name in Schedule II hereto.
3. Terms
of Offering. The Representatives have advised the Company that the Underwriters will, subject to the provisions hereof and the selling
restrictions disclosed in the Prospectus, make a public offering of their respective proportions of the Securities purchased by the Underwriters
hereunder as soon after the Registration Statement and this Agreement have become effective as in the judgment of the Representatives
is advisable. The Company is further advised by you that the Securities are to be offered to the public upon the terms set forth in the
Prospectus (including the selling and transfer restrictions contained therein).
4. Payment
and Delivery. Payment for the Securities shall be made to the Company in Federal or other funds immediately available in New York
City against delivery of such Securities for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on
August 18, 2026, or at such other time on the same or such other date as shall be designated in writing by the Representatives. The
time and date of such payment are hereinafter referred to as the “Closing Date.”
9
Payment for the Securities
shall be made against delivery, and the Securities shall be registered in such names and in such denominations as the Representatives
shall request in writing not later than one full business day prior to the Closing Date. The Securities shall be delivered to the Representatives
on the Closing Date for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer
of the Securities to the Underwriters duly paid, against payment of the purchase price therefor plus accrued interest, if any, to the
date of payment and delivery.
5. Conditions
to the Underwriters’ Obligations. The several obligations of the Underwriters to purchase and pay for the Securities on the
Closing Date are subject, in the discretion of the Representatives, to the condition that all representations and warranties and other
statements of the Company in this Agreement are, at and as of the Closing Date, true and correct, the condition that each of them shall
have performed in all material respects all of their respective obligations hereunder theretofore to be performed and to the following
additional conditions:
(a) Effectiveness
of Registration Statement; Filing of Prospectus. The Registration Statement has become effective and at the Closing Date and
no stop order suspending the effectiveness of the Registration Statement shall have been issued under the Securities Act or proceedings
therefor or pursuant to Section 8A under the Securities Act initiated or, to the knowledge of the Company, threatened by the Commission,
and any request on the part of the Commission for additional information shall have been complied with to the reasonable satisfaction
of counsel to the Underwriters. The filings required under Rule 424(b) shall have been filed with the Commission in the manner
and within the time period required by Rule 424(b) (or a post-effective amendment providing such information shall have been
filed and become effective in accordance with the requirements of Rule 430B). The Final Term Sheet (as defined herein) and any other
material required to be filed by the Company pursuant to Rule 433(d) under the rules and regulations under the Securities
Act shall have been timely filed;
(b) Opinion
and Negative Assurance Letters of Counsel for the Underwriters. The Underwriters shall have received on the Closing Date an opinion
and negative assurance letter of Davis Polk & Wardwell LLP, counsel for the Underwriters, dated the Closing Date, with respect
to such matters as may be reasonably requested by the Underwriters;
(c) Opinion
of the Company’s Internal Counsel. The Underwriters shall have received on the Closing Date an opinion letter of Emily A. Weith,
Vice President, Corporate Legal, Governance, and Assistant Secretary (or such other person who shall be a senior legal officer of the
Company on the Closing Date), dated the Closing Date, in form and substance satisfactory to the Underwriters;
(d) Opinion
and Negative Assurance Letters of Counsel for the Company. The Underwriters shall have received on the Closing Date an opinion letter
of Wachtell, Lipton, Rosen & Katz, outside counsel for the Company, dated the Closing Date, in form and substance satisfactory
to the Underwriters, and a negative assurance letter, dated the Closing Date, in form and substance satisfactory to the Underwriters;
10
(e) Accountant’s
Comfort Letters. The Underwriters shall have received on each of the date hereof and the Closing Date a letter, dated the date hereof
or the Closing Date, as applicable, in form and substance satisfactory to the Underwriters, from Ernst & Young LLP, independent
public accountants with respect to the Company’s consolidated financial statements and certain financial information included or
incorporated by reference in the Time of Sale Prospectus and the Prospectus, containing statements and information of the type ordinarily
included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial
information included or incorporated by reference in the Time of Sale Prospectus and the Prospectus; provided that the letter delivered
on the Closing Date shall use a “cut-off date” not earlier than the date hereof;
(f) No
Material Adverse Change. (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the
latest financial statements included in the Time of Sale Prospectus any loss or interference with its business from fire, explosion, flood
or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise
than as set forth or contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and (ii) since the
respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there
shall not have been any change in the consolidated capital stock or any increase in the consolidated long-term debt of the Company and
its subsidiaries, taken as a whole, or any change, or any development involving a prospective change, in or affecting the business, financial
position, shareholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, otherwise than as
set forth or contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the effect of which, in any such
case described in clause (i) or (ii) above, is in the reasonable judgment of the Representatives so material and
adverse as to make it impracticable or inadvisable to proceed with the offering or the delivery of the Securities on the terms and in
the manner contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus;
(g) No
Downgrade. On or after the date of this Agreement (i) no downgrading shall have occurred, nor shall any notice have been given
of any intended or potential downgrading, in the rating accorded the Company (if any) or any of the securities of the Company or any of
its subsidiaries by Moody’s Investor Services or Standard & Poor’s Ratings Service and (ii) neither organization
shall have publicly announced that it has under surveillance or review, with possible negative implications, its rating of any of the
Company’s debt securities;
(h) Officers’
Certificate. The Company shall have furnished or caused to be furnished to the Representatives on the Closing Date a certificate
of two officers of the Company, satisfactory to the Representatives as to the accuracy of the representations and warranties of the Company
herein at and as of the Closing Date, as to the performance by the Company of all of its respective obligations hereunder to be performed
at or prior to the Closing Date and as to the matters set forth in Sections 5(f) and 5(g) above;
and
(i) Chief
Financial Officer’s Certificate. On the date hereof and on the Closing Date, the Company shall have furnished to the Representatives
a certificate, dated the respective date of delivery thereof, of Scott T. Reents, Chief Financial Officer of the Company, in form and
substance satisfactory to the Representatives and covering such matters as the Representatives may reasonably request.
11
6. Covenants
of the Company. The Company covenants to each Underwriter as follows:
(a) Compliance
with Securities Regulations and Commission Requests. The Company will comply with the requirements of Rule 430B and will notify
the Representatives immediately, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement
or new registration statement relating to the Securities shall become effective, or any supplement to the Prospectus or any amended Prospectus
shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any
amendment to the Registration Statement or the filing of a new registration statement or any amendment or supplement to the Prospectus
or any document incorporated by reference therein or otherwise deemed to be a part thereof or for additional information relating to the
Registration Statement or the Prospectus, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement or such new registration statement or of any order preventing or suspending the use of any preliminary prospectus,
or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceedings for any of such purposes or of any examination pursuant to Section 8(e) of the Securities Act concerning
the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act
in connection with the offering of the Securities. The Company will effect the filings required under Rule 424(b), in the manner
and within the time period required by Rule 424(b), and will take such steps as it deems necessary to ascertain promptly whether
the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event
that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop
order and, if any stop order is issued, to obtain the lifting thereof at the earliest possible moment;
(b) Delivery
of Prospectus. To furnish to the Representatives in New York City, without charge, prior to 10:00 a.m. New York City time on
the second business day next succeeding the date of this Agreement and during the period mentioned in Section 6(e) or
Section 6(f), as many copies of the Time of Sale Prospectus, the Prospectus, any documents incorporated by reference therein
and any supplements and amendments thereto as the Representatives may reasonably request;
(c) Delivery
of Registration Statement. Before amending or supplementing the Registration Statement, the Time of Sale Prospectus or the Prospectus
during any period when a prospectus relating to the Securities is required to be delivered under the Securities Act, to furnish to the
Representatives a copy of each such proposed amendment or supplement and not to file any such proposed amendment or supplement to which
the Representatives reasonably object, except as may be required by applicable law;
(d) Issuer
Free Writing Prospectuses. To furnish to the Representatives a copy of each proposed free writing prospectus to be prepared by or
on behalf of, used by, or referred to by the Company and not to use or refer to any proposed free writing prospectus to which the Representatives
reasonably object; not to take any action that would result in an Underwriter or the Company being
required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by
or on behalf of the Underwriter that the Underwriter otherwise would not have been required to file thereunder;
12
(e) Continued
Compliance with Securities Laws. If the Time of Sale Prospectus is being used to solicit offers to buy the Securities at a time when
the Prospectus is not yet available to prospective purchasers and any event shall occur or condition exist as a result of which it is
necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances,
not misleading, any event shall occur or condition exist as a result of which the Time of Sale Prospectus
conflicts with the information contained in the Registration Statement then on file, or
if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with
applicable law, forthwith to prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer
upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as
so amended or supplemented will not, in the light of the circumstances when the Time of Sale Prospectus is delivered to a prospective
purchaser, be misleading or so that the Time of Sale Prospectus, as amended or supplemented, will
no longer conflict with the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply
with applicable law; provided that all such amendments or supplements comply with Section 6(c) hereof;
(f) Filing
of Amendments. If, during such period after the first date of the public offering of the Securities as in the opinion of counsel for
the Underwriters the Prospectus (or in lieu thereof the notice referred to in Rule 173(a) of
the Securities Act) is required by law to be delivered in connection with sales by an Underwriter or
dealer, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus in
order to make the statements therein, in the light of the circumstances when the Prospectus (or
in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, not misleading,
or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply with applicable
law, forthwith to prepare, file with the Commission and furnish, at its own expense (unless such amendment or supplement shall be made
more than six months after the date of this Agreement, in which case at the sole expense of the Underwriters), to the Underwriters and
to the dealers (whose names and addresses you will furnish to the Company) to which Securities may have been sold by you on behalf of
the Underwriters and to any other dealers upon request, either amendments or supplements to the Prospectus so that the statements
in the Prospectus as so amended or supplemented will not, in the light of the circumstances when the Prospectus (or
in lieu thereof the notice referred to in Rule 173(a) of the Securities Act) is delivered to a purchaser, be misleading
or so that the Prospectus, as amended or supplemented, will comply with applicable law; provided that all such amendments or supplements
comply with Section 6(c) hereof;
(g) Blue
Sky Qualifications. To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions
as the Representatives shall reasonably request and to continue such qualifications, if any, in effect so long as required for the underwriting
of the Securities by the Underwriters; provided that the Company shall not be required to qualify as a foreign corporation or to
file a general consent to service of process in any jurisdiction or subject itself to taxation in a jurisdiction in which it is not otherwise
subject;
(h) Earnings
Statement. To make generally available to the Company’s security holders and to you as soon as practicable an earnings statement
covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement
which shall satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission
thereunder;
13
(i) Fees
and Expenses. Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to
pay or cause to be paid the following: (i) the fees, disbursements and expenses of the counsel and accountants for the Company
in connection with the registration and delivery of the Securities under the Securities Act and all other fees or expenses in
connection with the preparation and filing of the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, the Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the
Company and amendments and supplements to any of the foregoing, including the filing fees payable to the Commission relating to the
Securities (within the time required by Rule 456(b)(1), if applicable), amendments and supplements thereto and the
mailing and delivering of copies thereof to the Underwriters and dealers along with all necessary issue, transfer, stamp, and other
similar taxes in connection therewith and or otherwise in connection with the issuance and sale of the Securities to the
Underwriters; (ii) the cost of printing or producing this Agreement, the Indenture, any Blue Sky survey and any other documents
in connection with the offering, purchase, sale and delivery of the Securities; (iii) all expenses in connection with the
qualification of the Securities for offering and sale under state securities laws as provided in Section 6(g) hereof,
including the reasonable fees and disbursements of counsel for the Underwriters in connection with such qualification and in
connection with the Blue Sky or legal investment memorandum; (iv) any reasonable fees charged by securities rating services for
rating the Securities; (v) the fees and expenses of the Trustee and any agent of the Trustee and the fees and disbursements of
counsel for any Trustee in connection with the Indenture and the Securities; and (vi) all
filing fees and the reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the review and
qualification of the offering of the Securities by the Financial Industry Regulatory Authority, and all other costs and
expenses incident to the performance of their obligations hereunder which are not otherwise specifically provided for in this Section 6.
It is understood, however, that, except as provided in this Section 6 and Sections 7 and 10
hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, transfer taxes on the
transfer of any of the Securities by them, and any advertising expenses connected with any offers they may make; each Underwriter
agrees to pay the portion of such expenses represented by such Underwriter’s pro rata share (based on the proportion that the
principal amount of Securities set forth opposite each Underwriter’s name in Schedule II bears to the aggregate
principal amount of Securities set forth opposite the names of all Underwriters) of the Securities;
(j) Regulation
M. Not to take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities
contemplated hereby;
(k) Use
of Proceeds. To use the proceeds from the sale of the Securities in the manner described in the Time of Sale Prospectus and the Prospectus;
(l) Delivery
of Documents. During the period of one year hereafter, the Company will furnish to the Underwriters, as soon as available, a copy
of each of the reports, notices or communications sent to securityholders, if not available on the Commission’s Electronic Data
Gathering, Analysis and Retrieval system;
14
(m) Compliance
with the Securities Act. The Company has not distributed and, prior to the later to occur of (i) the Closing Date and (ii) the
completion of the distribution of the Securities, will not distribute any material in connection with the offering and sale of the Securities,
other than the Time of Sale Prospectus and the Prospectus or other materials, if any, permitted by the Securities Act, or regulations
promulgated pursuant to the Securities Act, and approved by the parties to this Agreement;
(n) Preparation
of a Final Term Sheet. To prepare a final term sheet relating to the offering of the Securities (a “Final Term Sheet”),
containing only information that describes the final terms of the Securities or the offering in a form consented to by the Underwriters,
and to file such final term sheet within the period required by Rule 433(d)(5)(ii) under the Securities Act following the date
the final terms have been established for the offering of the Securities; and
(o) Restriction
on Sale of Securities. The Company also agrees that, without the prior written consent of the Representatives on behalf of the Underwriters,
it will not, during the period beginning on the date hereof and continuing to and including the Closing Date, offer, sell, contract to
sell or otherwise dispose of any debt securities of the Company or warrants to purchase debt securities of the Company substantially similar
to the Securities (other than the sale of the Securities under this Agreement or securities or warrants permitted with the prior written
consent of the Representatives identified in Schedule I with the authorization to release this lock-up on behalf of the Underwriters).
7. Covenants
of the Underwriters. Each Underwriter severally covenants with the Company not to take any action
that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared
by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for the action of
the Underwriter.
8. Indemnity
and Contribution.
(a) The
Company will indemnify and hold harmless each Underwriter, its directors, officers and employees, each person, if any, who controls any
Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and each affiliate
of any Underwriter within the meaning of Rule 405 under the Securities Act, from and against any and all losses, claims, damages
and liabilities, joint or several, to which such Underwriter, director, officer, employee, controlling person or affiliate may become
subject under such Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
the Time of Sale Prospectus or any amendment or supplement thereto, any free writing prospectus as
defined in Rule 433(h) under the Securities Act, any Company information that the
Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act, any “road show” as
defined in Rule 433(h) under the Securities Act (a “road show”), the Prospectus or any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact necessary in order
to make the statements therein in the light of the circumstances under which they were made not misleading, and will reimburse each Underwriter,
director, officer, employee, controlling person or affiliate for any legal or other expenses reasonably incurred by such Underwriter,
director, officer, employee or controlling person in connection with investigating or defending any such loss, damage, liability, action
or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent
that any such loss, harm, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission
or alleged omission made in the Prospectus or any free writing prospectus or any amendment or supplement thereto in reliance upon and
in conformity with the Underwriters’ Information (as defined in Section 8(b) below) relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, and provided further, that
the foregoing indemnity agreement shall not inure to the benefit of any Underwriter from whom the person asserting any such loss, liability,
claim, damage or expense purchased Securities, or any person controlling such Underwriter, if the Company provides a copy of an amendment
or supplement to the Prospectus or any free writing prospectus as theretofore provided to such Underwriter by the Company (with notice
that such amendment or supplement contains additional or different material information from that previously provided) sufficiently far
enough in advance of the time of sale in order to enable such Underwriter to convey such amendment or supplement to the purchaser of the
Securities, and such amendment or supplement (x) was not conveyed by or on behalf of such Underwriter to such person at or prior
to the entry into the contract of sale of the Securities by such person, and (y) would have cured the defect giving rise to such
loss, liability, claim, damage or expense.
15
(b) Each
Underwriter will, severally and not jointly, indemnify and hold harmless the Company and its respective directors, officers and employees
and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act against any losses, claims, damages or liabilities to which the Company or any of its respective directors, officers,
employees or controlling persons may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or
liability (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material
fact contained in any Registration Statement, the Time of Sale Prospectus, any preliminary prospectus, free writing prospectus, road show
or the Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state
therein a material fact necessary in order to make the statements therein not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement, or omission or alleged omission was made in any Registration Statement,
the Time of Sale Prospectus, any preliminary prospectus, free writing prospectus or the Prospectus, or any such amendment or supplement,
in reliance upon and conformity with written information furnished to the Company by such Underwriter through the Representatives expressly
for use therein; and each Underwriter will reimburse the Company, or any director, officer, employee or controlling person of the Company,
for any legal or other expenses reasonably incurred by the Company, or any such director, officer, employee or controlling person in connection
with investigating, or defending any such loss, damage, liability, action or claim as such expenses are incurred, but only with reference
to the Underwriters’ Information (defined below) relating to such Underwriter furnished to the Company in writing by such Underwriter
through you expressly for use in the Registration Statement, the Time of Sale Prospectus, any free writing prospectus or the Prospectus
or any amendment or supplement thereto. The Company hereby acknowledges that the only such information are the statements set forth in
the first and second paragraphs under the sub-heading “Stabilization and Short Positions,” in each case under the caption
“Underwriting” in the Time of Sale Prospectus and the Prospectus (collectively, the “Underwriters’ Information”).
16
(c) Promptly
after receipt by an indemnified party under Sections 8(a) and 8(b) above of notice
of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying
party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying
party shall not relieve it from any liability which it may have to any indemnified party except to the extent such omission materially
prejudices the indemnifying party. In case any such action shall be brought against any indemnified party, the indemnifying party shall
be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified,
to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent
of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party
of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection
for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection
with the defense thereof other than reasonable costs of investigation.
(d) To
the extent the indemnification provided for in Sections 8(a) and 8(b) is unavailable
to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein (or actions in respect
thereof), then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute
to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion
as is appropriate to reflect the relative benefits received by the Company, on the one hand and the Underwriters on the other hand from
the offering of the Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law or if the indemnified party failed to give notice required under Section 8(c) above, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of
the Company on the one hand and of the Underwriters on the second hand in connection with the statements or omissions that resulted in
such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The
relative benefits received by the Company on the one hand and the Underwriters on the other hand in connection with the offering of the
Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (before deducting
expenses) received by the Company and the total discounts and commissions received by the Underwriters bear to the aggregate offering
price of the Securities. The relative fault of the Company on the one hand and of the Underwriters on the other hand shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission. The Underwriters’ respective
obligations to contribute pursuant to this Section 8 are several in proportion to the respective principal amount of Securities
they have purchased hereunder, and not joint.
(e) The
Company and the Underwriters agree that it would not be just or equitable if contribution pursuant to this Section 8 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed
to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, no Underwriter
shall be required to contribute any amount in excess of the amount by which the total price at which the Securities underwritten by it
and distributed to the public were offered to the public exceeds the amount of any damages that such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any
rights or remedies which may otherwise be available to any indemnified party at law or in equity.
17
(f) The
indemnifying party under this Section 8 shall not be liable for any settlement of any proceeding effected without its written
consent but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify
the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or final judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by this Section 8, the indemnifying party agrees that it shall be liable
for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days
after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the
indemnified party in accordance with such request or disputed in good faith the indemnified party’s entitlement to such reimbursement
prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect
any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which
any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless
such settlement, compromise or consent (i) includes an unconditional release of such indemnified party from all liability on claims
that are the subject matter of such action, suit or proceeding and (ii) does not include any statements as to or any findings of
fault, culpability or failure to act by or on behalf of any indemnified party.
(g) The
indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements
of the Company contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination
of this Agreement, (ii) any investigation made by or on behalf of any Underwriter, any person controlling any Underwriter or any
affiliate of any Underwriter or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii) acceptance
of and payment for any of the Securities.
9. Termination.
The Underwriters may terminate this Agreement by notice given by Representatives to the Company, if after the execution and delivery of
this Agreement and prior to the Closing Date there shall have occurred (i) a suspension of trading of the Company’s common
shares by the Commission or the New York Stock Exchange; (ii) a suspension or material limitation in trading in securities generally
on the New York Stock Exchange; (iii) a general moratorium on commercial banking activities in New York declared by either Federal
or New York State authorities; (iv) a material disruption in commercial banking or securities settlement, payment or clearance services
in the United States; or (v) the outbreak or escalation of hostilities or the occurrence of any other calamity or crisis or any material
adverse change in financial markets, if the effect of any such event specified in this clause (v) makes it, in the Representatives’
judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated
in the Time of Sale Prospectus or the Prospectus.
18
10. Effectiveness;
Defaulting Underwriters. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.
If, on the Closing Date, any
one or more of the Underwriters shall fail or refuse to purchase the Securities that it has or they have agreed to purchase hereunder
on such date, and the aggregate principal amount of the Securities which such defaulting Underwriter or Underwriters agreed but failed
or refused to purchase is not more than one-tenth of the aggregate principal amount of the Securities to be purchased on such date, the
other Underwriters shall be obligated severally in the proportions that the principal amount of the Securities set forth opposite their
respective names in Schedule II bears to the aggregate principal amount of the Securities set forth opposite the names of all such
non-defaulting Underwriters, or in such other proportions as the Representatives may specify, to purchase the portion of such Underwriters’
Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date; provided that
in no event shall the principal amount of the Securities that any Underwriter has agreed to purchase pursuant to this Agreement be increased
pursuant to this Section 10 by an amount in excess of one-ninth of such principal amount of the Securities without the
written consent of such Underwriter. If, on the Closing Date any Underwriter or Underwriters shall fail or refuse to purchase Securities
and the aggregate principal amount of the Securities with respect to which such default occurs is more than one-tenth of the aggregate
principal amount of the Securities to be purchased on such date, and arrangements satisfactory to the Representatives, the Company, for
the purchase of such Securities are not made within 36 hours after such default, this Agreement shall terminate without liability on the
part of any non-defaulting Underwriter and the Company. In any such case, either the Representatives or the Company shall have the right
to postpone the Closing Date, but in no event for longer than seven days, in order that the required changes, if any, in the Registration
Statement, in the Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be effected. Any action taken
under this paragraph shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement.
If this Agreement shall be
terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms
or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under
this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to
themselves, severally, for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such
Underwriters in connection with this Agreement or the offering contemplated hereunder but the Company shall then be under no further liability
to any Underwriter with respect to this Agreement except as provided in Section 6(i) and Section 8 hereof.
11. Entire
Agreement. This Agreement, together with any contemporaneous written agreements and any prior written agreements (to the extent not
superseded by this Agreement) that relate to the offering of the Securities, represents the entire agreement between the Company and the
Underwriters with respect to the preparation of any preliminary prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of
the offering, and the purchase and sale of the Securities.
12. Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of
the parties and delivered (by telecopy, electronic delivery or otherwise) to the other parties. Signatures to this Agreement transmitted
by facsimile transmission, by electronic mail (including any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act or other applicable law, e.g., www. Docusign.com) in “portable document format” (“.pdf”)
form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the
same effect as physical delivery of the paper document bearing the original signature.
19
13. Applicable
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.
14. Headings.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of
this Agreement.
15. Notices.
All communications hereunder shall be in writing and effective only upon receipt and if to the Underwriters shall be delivered, mailed
or sent to the Representatives in care of Morgan Stanley & Co. LLC, 1585 Broadway, 29th Floor, New York, New York
10036, Attention: Investment Banking Division, Fax: 212-507-8999; BofA Securities, Inc., 114 West 47th Street, NY8-114-07-01,
New York, New York 10036, Attention: High Grade Debt Capital Markets Transaction Management/Legal, Fax: 212-901-7881; J.P. Morgan Securities
LLC, 270 Park Avenue, New York, New York 10017, Attention: Investment Grade Syndicate Desk, Fax: 212-834-6081; SG Americas Securities,
LLC, 245 Park Avenue, New York, New York 10167, Attention: High Grade Syndicate Desk, Email: list.us-glfi-syn-cap@sgcib.com; and if to
the Company, shall be delivered, mailed or sent to AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, Attention:
Treasurer.
16. Recognition
of the U.S. Special Resolution Regimes.
(a) In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.
(b) In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.
For purposes of this Section 16,
“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance
with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a “covered entity”
as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as
that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that
term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). “Default Right” has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable. “U.S.
Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
[Signature pages follow]
20
Very truly yours,
ABBVIE INC.
By:
/s/ Stefan Geldemeyer
Name: Stefan Geldemeyer
Title: Vice President and Corporate Treasurer
[Signature page to the Underwriting Agreement]
Accepted as of the date hereof
Morgan Stanley & Co. LLC
BofA Securities, Inc.
J.P. Morgan Securities LLC
SG Americas Securities, LLC
Acting severally on behalf of themselves and the
several
Underwriters named in Schedule II hereto.
Morgan Stanley & Co. LLC
By:
/s/ Thomas Hadley
Name: Thomas Hadley
Title: Managing Director
BofA Securities, Inc.
By:
/s/ Kevin Wehler
Name: Kevin Wehler
Title: Managing Director
J.P. Morgan Securities LLC
By:
/s/ Saee Athalye
Name: Saee Athalye
Title: Vice President
SG Americas Securities, LLC
By:
/s/ Sabina R. Ceddia
Name: Sabina R. Ceddia
Title: Director
[Signature page to the Underwriting
Agreement]
SCHEDULE I
Representatives:
Representatives to release lock-up under Section 6(o):
Morgan Stanley & Co. LLC
BofA Securities, Inc.
J.P. Morgan Securities LLC
SG Americas Securities, LLC
Representatives authorized to appoint
counsel under Section 8(c):
Morgan Stanley & Co. LLC
BofA Securities, Inc.
J.P. Morgan Securities LLC
SG Americas Securities, LLC
Indenture:
Indenture dated as of November 8, 2012, as supplemented by Supplemental Indenture No. 13 to be dated August 18, 2026 in each case between the Company and the Trustee
Trustee:
U.S. Bank Trust Company, National Association
Registration Statement File No.:
333-284980
Time of Sale Prospectus:
1. Basic
Prospectus dated February 14, 2025 relating to the Shelf Securities
2. The preliminary prospectus supplement dated August 4, 2026 relating to the Securities
3. Free
writing prospectus dated August 4, 2026 containing a description of certain terms filed by the Company under Rule 433(d) of
the Securities Act
Securities to be Purchased:
Senior Floating Rate Notes due 2028
4.500% Senior Notes due 2028
4.650% Senior Notes due 2030
4.875% Senior Notes due 2031
5.050% Senior Notes due 2033
5.300% Senior Notes due 2036
5.450% Senior Notes due 2038
6.000% Senior Notes due 2056
6.100% Senior Notes due 2066
Aggregate Principal Amount:
$500,000,000 Senior Floating Rate Notes due 2028
$1,000,000,000 4.500% Senior Notes due 2028
$1,250,000,000 4.650% Senior Notes due 2030
$1,500,000,000 4.875% Senior Notes due 2031
S-1-1
$1,250,000,000 5.050% Senior Notes due 2033
$1,500,000,000 5.300% Senior Notes due 2036
$1,000,000,000 5.450% Senior Notes due 2038
$1,500,000,000 6.000% Senior Notes due 2056
$500,000,000 6.100% Senior Notes due 2066
Purchase Price:
99.850% of the principal amount of the Senior Floating Rate Notes due
2028
99.820% of the principal amount of the 4.500% Senior Notes due 2028
99.612% of the principal amount of the 4.650% Senior Notes due 2030
99.627% of the principal amount of the 4.875% Senior Notes due 2031
99.514% of the principal amount of the 5.050% Senior Notes due 2033
99.382% of the principal amount of the 5.300% Senior Notes due 2036
99.335% of the principal amount of the 5.450% Senior Notes due 2038
98.691% of the principal amount of the 6.000% Senior Notes due 2056
99.093% of the principal amount of the 6.100% Senior Notes due 2066
Maturity:
Senior Floating Rate Notes due 2028: August 18, 2028
4.500% Senior Notes due 2028: August 18, 2028
4.650% Senior Notes due 2030: March 15, 2030
4.875% Senior Notes due 2031: September 15, 2031
5.050% Senior Notes due 2033: September 15, 2033
5.300% Senior Notes due 2036: September 15, 2036
5.450% Senior Notes due 2038: September 15, 2038
6.000% Senior Notes due 2056: September 15, 2056
6.100% Senior Notes due 2066: September 15, 2066
Interest Rate:
Senior Floating Rate Notes due 2028: Compounded SOFR + 42 bps, accruing
from and including August 18, 2026
4.500% Senior Notes due 2028: 4.500% per annum, accruing from August 18,
2026
4.650% Senior Notes due 2030: 4.650% per annum, accruing from August 18,
2026
S-1-2
4.875% Senior Notes due 2031: 4.875% per annum, accruing from August 18,
2026
5.050% Senior Notes due 2033: 5.050% per annum, accruing from August 18,
2026
5.300% Senior Notes due 2036: 5.300% per annum, accruing from August 18,
2026
5.450% Senior Notes due 2038: 5.450% per annum, accruing from August 18,
2026
6.000% Senior Notes due 2056: 6.000% per annum, accruing from August 18,
2026
6.100% Senior Notes due 2066: 6.100% per annum, accruing from August 18,
2026
Interest Payment Dates:
Senior Floating Rate Notes due 2028: February 18, May 18,
August 18 and November 18, commencing November 18, 2026
4.500% Senior Notes due 2028: February 18 and August 18,
commencing February 18, 2027
4.650% Senior Notes due 2030: March 15 and September 15,
commencing March 15, 2027
4.875% Senior Notes due 2031: March 15 and September 15,
commencing March 15, 2027
5.050% Senior Notes due 2033: March 15 and September 15,
commencing March 15, 2027
5.300% Senior Notes due 2036: March 15 and September 15,
commencing March 15, 2027
5.450% Senior Notes due 2038: March 15 and September 15,
commencing March 15, 2027
6.000% Senior Notes due 2056: March 15 and September 15,
commencing March 15, 2027
6.100% Senior Notes due 2066: March 15 and September 15,
commencing March 15, 2027
Closing Date and Time:
August 18, 2026, 10:00 a.m.
Closing Location:
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017
Address for Notices to Underwriters:
Morgan Stanley & Co. LLC
1585 Broadway, 29th Floor
New York, New York 10036
Attention: Investment Banking Division
Fax: 212-507-8999;
BofA Securities, Inc.
114 West 47th Street
NY8-114-07-01
New York, New York 10036
S-1-3
Attention: High Grade Debt Capital Markets
Transaction Management/Legal
Fax: 212-901-7881;
J.P. Morgan Securities LLC
270 Park Avenue
New York, New York 10017
Attention: Investment Grade Syndicate Desk
Fax: 212-834-6081;
SG Americas Securities, LLC
245 Park Avenue
New York, New York 10167
Attention: High Grade Syndicate Desk
Email: list.us-glfi-syn-cap@sgcib.com
Address for Notices to the Company:
AbbVie Inc.
1 North Waukegan Road
North Chicago, Illinois 60064
Attention: Treasurer
S-1-4
SCHEDULE II
Underwriter
Principal
Amount of
2028 Floating
Rate Notes to
be Purchased
Principal
Amount of
2028 Notes to
be Purchased
Principal
Amount of
2030 Notes to
be Purchased
Principal
Amount of
2031 Notes to
be Purchased
Principal
Amount of
2033 Notes to
be Purchased
Principal
Amount of
2036 Notes to
be Purchased
Principal
Amount of
2038 Notes to
be Purchased
Principal
Amount of
2056 Notes to
be Purchased
Principal
Amount of
2066 Notes to
be Purchased
Morgan Stanley & Co. LLC
$
75,000,000
$
150,000,000
$
187,500,000
$
225,000,000
$
187,500,000
$
225,000,000
$
150,000,000
$
225,000,000
$
75,000,000
BofA Securities, Inc.
$
75,000,000
$
150,000,000
$
187,500,000
$
225,000,000
$
187,500,000
$
225,000,000
$
150,000,000
$
225,000,000
$
75,000,000
J.P. Morgan Securities LLC
$
75,000,000
$
150,000,000
$
187,500,000
$
225,000,000
$
187,500,000
$
225,000,000
$
150,000,000
$
225,000,000
$
75,000,000
SG Americas Securities, LLC
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
Barclays Capital Inc.
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
BNP Paribas Securities Corp.
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
HSBC Securities (USA) Inc.
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
Citigroup Global Markets Inc.
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
Deutsche Bank Securities Inc.
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
Mizuho Securities USA LLC
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
Wells Fargo Securities, LLC
$
27,000,000
$
54,000,000
$
67,500,000
$
81,000,000
$
67,500,000
$
81,000,000
$
54,000,000
$
81,000,000
$
27,000,000
MUFG Securities Americas Inc.
$
9,800,000
$
19,600,000
$
24,500,000
$
29,400,000
$
24,500,000
$
29,400,000
$
19,600,000
$
29,400,000
$
9,800,000
U.S. Bancorp Investments, Inc.
$
9,800,000
$
19,600,000
$
24,500,000
$
29,400,000
$
24,500,000
$
29,400,000
$
19,600,000
$
29,400,000
$
9,800,000
Lloyds Securities Inc.
$
9,800,000
$
19,600,000
$
24,500,000
$
29,400,000
$
24,500,000
$
29,400,000
$
19,600,000
$
29,400,000
$
9,800,000
Santander US Capital Markets LLC
$
9,800,000
$
19,600,000
$
24,500,000
$
29,400,000
$
24,500,000
$
29,400,000
$
19,600,000
$
29,400,000
$
9,800,000
TD Securities (USA) LLC
$
9,800,000
$
19,600,000
$
24,500,000
$
29,400,000
$
24,500,000
$
29,400,000
$
19,600,000
$
29,400,000
$
9,800,000
Siebert Williams Shank & Co., LLC
$
5,000,000
$
10,000,000
$
12,500,000
$
15,000,000
$
12,500,000
$
15,000,000
$
10,000,000
$
15,000,000
$
5,000,000
R. Seelaus & Co., LLC
$
1,000,000
$
2,000,000
$
2,500,000
$
3,000,000
$
2,500,000
$
3,000,000
$
2,000,000
$
3,000,000
$
1,000,000
Blaylock Van, LLC
$
1,000,000
$
2,000,000
$
2,500,000
$
3,000,000
$
2,500,000
$
3,000,000
$
2,000,000
$
3,000,000
$
1,000,000
Independence Point Securities LLC
$
1,000,000
$
2,000,000
$
2,500,000
$
3,000,000
$
2,500,000
$
3,000,000
$
2,000,000
$
3,000,000
$
1,000,000
Penserra Securities LLC
$
1,000,000
$
2,000,000
$
2,500,000
$
3,000,000
$
2,500,000
$
3,000,000
$
2,000,000
$
3,000,000
$
1,000,000
CastleOak Securities, L.P.
$
1,000,000
$
2,000,000
$
2,500,000
$
3,000,000
$
2,500,000
$
3,000,000
$
2,000,000
$
3,000,000
$
1,000,000
Total
$
500,000,000
$
1,000,000,000
$
1,250,000,000
$
1,500,000,000
$
1,250,000,000
$
1,500,000,000
$
1,000,000,000
$
1,500,000,000
$
500,000,000
S-2-1
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
Aug. 04, 2026
Document Information [Line Items]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 04, 2026
Entity File Number
001-35565
Entity Registrant Name
ABBVIE
INC.
Entity Central Index Key
0001551152
Entity Tax Identification Number
32-0375147
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
1
North Waukegan Road
Entity Address, City or Town
North
Chicago
Entity Address, State or Province
IL
Entity Address, Postal Zip Code
60064-6400
City Area Code
847
Local Phone Number
932-7900
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
Common
Stock, $0.01 Par Value
Trading Symbol
ABBV
Security Exchange Name
NYSE
Senior Notes 0. 750 Percentdue 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
0.750%
Senior Notes due 2027
Trading Symbol
ABBV27
Security Exchange Name
NYSE
Senior Notes 2. 125 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
2.125%
Senior Notes due 2028
Trading Symbol
ABBV28
Security Exchange Name
NYSE
Senior Notes 2. 625 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
2.625%
Senior Notes due 2028
Trading Symbol
ABBV28B
Security Exchange Name
NYSE
Senior Notes 2. 125 Percentdue 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
2.125%
Senior Notes due 2029
Trading Symbol
ABBV29
Security Exchange Name
NYSE
Senior Notes 1. 250 Percentdue 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]
Document Information [Line Items]
Title of 12(b) Security
1.250%
Senior Notes due 2031
Trading Symbol
ABBV31
Security Exchange Name
NYSE
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details
Name:
dei_DocumentInformationLineItems
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
dei_EntityListingsExchangeAxis=exch_XNYS
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes0.750Percentdue2027Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2028Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.625Percentdue2028Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2029Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2031Member
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: